Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

767 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial.
Delahunt B, Steigler A, Atkinson C, Christie D, Duchesne G, Egevad L, Joseph D, Kenwright DN, Matthews J, Murray JD, Oldmeadow C, Samaratunga H, Spry NA, Thunders MC, Hondermarck H, Denham JW. Delahunt B, et al. Among authors: atkinson c. Pathology. 2022 Feb;54(1):49-54. doi: 10.1016/j.pathol.2021.11.004. Epub 2021 Dec 24. Pathology. 2022. PMID: 34955242
A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
Lamb DS, Denham JW, Joseph D, Matthews J, Atkinson C, Spry NA, Duchesne G, Ebert M, Steigler A, Delahunt B, D'Este C. Lamb DS, et al. Among authors: atkinson c. Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):385-91. doi: 10.1016/j.ijrobp.2009.10.071. Epub 2010 Mar 28. Int J Radiat Oncol Biol Phys. 2011. PMID: 20350786 Clinical Trial.
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Denham JW, et al. Among authors: atkinson c. Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14. Lancet Oncol. 2014. PMID: 25130995 Clinical Trial.
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Denham JW, et al. Among authors: atkinson c. Lancet Oncol. 2019 Feb;20(2):267-281. doi: 10.1016/S1470-2045(18)30757-5. Epub 2018 Dec 19. Lancet Oncol. 2019. PMID: 30579763 Clinical Trial.
Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.
Joseph D, Denham JW, Steigler A, Lamb DS, Spry NA, Stanley J, Shannon T, Duchesne G, Atkinson C, Matthews JHL, Turner S, Kenny L, Christie D, Tai KH, Gogna NK, Kearvell R, Murray J, Ebert MA, Haworth A, Delahunt B, Oldmeadow C, Attia J. Joseph D, et al. Among authors: atkinson c. Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):693-702. doi: 10.1016/j.ijrobp.2019.11.415. Int J Radiat Oncol Biol Phys. 2020. PMID: 32092343 Clinical Trial.
Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial.
Delahunt B, Murray JD, Steigler A, Atkinson C, Christie D, Duchesne G, Egevad L, Joseph D, Matthews J, Oldmeadow C, Samaratunga H, Spry NA, Srigley JR, Hondermarck H, Denham JW. Delahunt B, et al. Among authors: atkinson c. Histopathology. 2020 Aug;77(2):284-292. doi: 10.1111/his.14107. Epub 2020 Jun 18. Histopathology. 2020. PMID: 32285460
Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data.
Delahunt B, Egevad L, Srigley JR, Steigler A, Murray JD, Atkinson C, Matthews J, Duchesne G, Spry NA, Christie D, Joseph D, Attia J, Denham JW. Delahunt B, et al. Among authors: atkinson c. Pathology. 2015 Oct;47(6):520-5. doi: 10.1097/PAT.0000000000000318. Pathology. 2015. PMID: 26325671 Clinical Trial.
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.
Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Matthews J, Tai KH, Spry NA, Christie D, Gleeson PS, Greer PB, D'Este C; Trans-Tasman Radiation Oncology Group 96.01 Trialists. Denham JW, et al. Among authors: atkinson c. Lancet Oncol. 2008 Nov;9(11):1058-68. doi: 10.1016/S1470-2045(08)70236-5. Epub 2008 Oct 15. Lancet Oncol. 2008. PMID: 18929505
767 results